NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. NPCE shares have declined 12.7% in the past three months even as the company’s core responsive neurostimulation, or RNS, franchise has continued to strengthen. The pullback leaves investors weighing improving focal-epilepsy demand against a less certain regulatory path for idiopathic generalized epilepsy, or IGE.

The setup is mixed rather than one-sided. Better RNS growth, higher guidance and expanding platform capabilities support the business case, while the IGE setback adds timing and execution risk that could keep sentiment restrained.

NPCE’s Pullback Meets a Stronger RNS Business

Second-quarter RNS System revenues totaled $22.5 million, up 21.3% year over year. Growth primarily reflected more units sold, supported by higher initial implants and replacement procedures. That performance kept the core franchise on a better trajectory despite recent share weakness.

Commercial indicators moved in the same direction. NeuroPace reached record highs in active prescribers, active accounts and its patient pipeline during the quarter. The majority of growth still comes from Level 4 comprehensive epilepsy centers, while community referral efforts are intended to broaden the funnel.

NeuroPace, Inc. Price and EPS Surprise

NeuroPace, Inc. price-eps-surprise | NeuroPace, Inc. Quote

NeuroPace Raises Guidance as Core Demand Holds

Management raised full-year 2026 total revenue guidance to $99.5-$101.5 million from $99-$101 million. The underlying RNS revenue outlook remains $98.5-$100.5 million, representing 21%-23% growth from the current adult focal-epilepsy indication and excluding any contribution from IGE expansion.

Operating expectations also improved. Adjusted gross-margin guidance rose to 82%-83% from 81.5%-82.5%, while adjusted EBITDA loss guidance improved to $7.5-$8.5 million from $8.5-$9.5 million. Those changes provide a counterweight to the stock’s recent decline.

Image Source: Zacks Investment Research

NPCE’s IGE Setback Adds Regulatory Uncertainty

The main overhang is the FDA’s July 2026 determination that NeuroPace’s IGE premarket approval supplement was not approvable in its current form. The agency requested additional clinical information and further interaction, increasing uncertainty around the timing of a potentially meaningful indication expansion.

The questions centered on clinical benefit across patient subgroups and the clinical relevance of reducing generalized tonic-clonic seizures, rather than new safety concerns. NeuroPace plans additional analyses and supporting evidence. Medtronic plc MDT also markets deep brain stimulation for epilepsy, underscoring the established neuromodulation treatment landscape.

NeuroPace’s AI Push Broadens the Platform Story

NeuroPace launched ECoG Assistant during the second quarter, the first tool in its planned NeuroPace AI suite. The system is supported by more than 27 million proprietary intracranial EEG recordings and is designed to help clinicians identify electrographic events, review trends and assess circadian patterns more efficiently.

The pipeline extends beyond that launch. Remote care, automated detection, a multimodal foundational model and a next-generation RNS system could expand the platform beyond implant hardware, but each carries development, regulatory and adoption risk. LivaNova PLC LIVN, through VNS Therapy, is another neuromodulation provider serving drug-resistant epilepsy.

Image Source: Zacks Investment Research

NPCE’s Signals Point to a Balanced Setup

The pullback has improved the entry price, but the evidence does not point to an unqualified buying case. Core RNS demand is advancing and operating guidance has improved, while the IGE pathway remains less predictable and the broader innovation pipeline still requires successful execution.

NPCE currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of B and Momentum Score of B reflect more favorable growth and price-trend characteristics, while the Value Score of D is less supportive. Together, the signals favor a measured stance rather than an aggressive response to the decline. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research